azd2014 and Lymphoma--B-Cell

azd2014 has been researched along with Lymphoma--B-Cell* in 1 studies

Other Studies

1 other study(ies) available for azd2014 and Lymphoma--B-Cell

Article	Year
Rituximab (anti-CD20)-modified AZD-2014-encapsulated nanoparticles killing of B lymphoma cells. Artificial cells, nanomedicine, and biotechnology, 2018, Volume: 46, Issue:sup2 The mTOR signal pathway is often highly activated in B-cell non-Hodgkin's lymphoma (NHL) and promotes cancer progression and chemo-resistance. Therefore, the pathways of mTOR are an important target for drug development in this disease. In the current study, we developed a rituximab (anti-CD20)-modified mTOR inhibitor, AZD-2014, loaded into nanoparticles (Ab-NPs-AZD-2014) for trial of its anti-NHL effect. In a cultured NHL cell line, Ab-NPs-AZD-2014 inhibited cancer cell growth, induced cell apoptosis, and blocked activation of mTORC1 and mTORC2 in Raji cells. These results indicate that antibody modification and nanomaterial loading of AZD-2014 with anti-CD20 significantly improved efficacy of AZD-2014 against NHL cells. This approach may ultimately deserve testing in therapy against NHL. Topics: Apoptosis; Benzamides; Biological Transport; Capsules; Cell Line, Tumor; Drug Carriers; Drug Liberation; Humans; Lymphoma, B-Cell; Morpholines; Nanoparticles; Polyethylene Glycols; Polylactic Acid-Polyglycolic Acid Copolymer; Pyrimidines; Rituximab	2018

Article

Year

Rituximab (anti-CD20)-modified AZD-2014-encapsulated nanoparticles killing of B lymphoma cells.

Artificial cells, nanomedicine, and biotechnology, 2018, Volume: 46, Issue:sup2

The mTOR signal pathway is often highly activated in B-cell non-Hodgkin's lymphoma (NHL) and promotes cancer progression and chemo-resistance. Therefore, the pathways of mTOR are an important target for drug development in this disease. In the current study, we developed a rituximab (anti-CD20)-modified mTOR inhibitor, AZD-2014, loaded into nanoparticles (Ab-NPs-AZD-2014) for trial of its anti-NHL effect. In a cultured NHL cell line, Ab-NPs-AZD-2014 inhibited cancer cell growth, induced cell apoptosis, and blocked activation of mTORC1 and mTORC2 in Raji cells. These results indicate that antibody modification and nanomaterial loading of AZD-2014 with anti-CD20 significantly improved efficacy of AZD-2014 against NHL cells. This approach may ultimately deserve testing in therapy against NHL.

Topics: Apoptosis; Benzamides; Biological Transport; Capsules; Cell Line, Tumor; Drug Carriers; Drug Liberation; Humans; Lymphoma, B-Cell; Morpholines; Nanoparticles; Polyethylene Glycols; Polylactic Acid-Polyglycolic Acid Copolymer; Pyrimidines; Rituximab

2018